The Company

Our Mission:

We are Anchiano Therapeutics, a pivotal-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel targeted therapies to treat cancer.

Our Science:

Clinical Program:

  • Gene therapy for early stage bladder cancer       

Preclinical Programs:  

  • Small molecule pan-RAS inhibitors
  • Small molecule PDE10/ß-catenin inhibitors

Our pivotal-stage clinical program is gene therapy for early stage bladder cancer. Inodiftagene vixteplasmid (formerly BC-819) is under development as a treatment for non-muscle-invasive bladder cancer (NMIBC). Inodiftagene has been tested in six clinical trials to date, three of which are in NMIBC. The pivotal development program comprises two registrational trials in NMIBC. The first of these, the Codex Trial, opened in December of 2018 and is recruiting patients now. For more information, click here or visit ClinicalTrials.gov (Identifier: NCT03719300). 

We have a partnership with ADT Pharmaceuticals around two small molecule development programs targeting oncogenic pathways, focused on RAS and PDE10/ß-catenin, respectively.  

Our Core Values:

  • Science – we are dedicated to the highest level of scientific innovation and research.
  • Compassion – we value life and we devote our resources to its preservation and improvement.
  • Excellence – we set high standards and pursue our work with passion. 
  • Achievement – we set aggressive goals with confidence in our ability and perseverance to achieve them.
  • Integrity – we conduct ourselves with honesty and the highest ethical standards. 
  • Focus on Patients – we are committed to the development of novel therapies that benefit patients and society. 

We are located in Cambridge, Massachusetts, and in Jerusalem, Israel and are publicly traded on the Nasdaq (NASDAQ: ANCN).